Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

34.66
-0.1046-0.30%
Post-market: 34.760.1046+0.30%16:10 EDT
Volume:188
Turnover:7K
Market Cap:16.29M
PE:- -
High:34.66
Open:34.76
Low:34.66
Close:34.76
52wk High:37.90
52wk Low:30.79
Shares:469.95K
Float Shares:469.95K
Volume Ratio:0.58
T/O Rate:0.04%
Dividend:0.41
Dividend Rate:1.18%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Alkermes - Phase 2 Study of Alks 7290 in Adults with Adhd Enrolling, Data Expected in 2027

THOMSON REUTERS
·
Sep 21

Oura - Eli Lilly Interested in Purchasing up to $100 Mln; Dragoneer up to $300 Mln in IPO - SEC Filing

THOMSON REUTERS
·
Sep 21

Novo Says Its Next-Gen Obesity Drug Tops Lilly Rival in Late-Stage Study

Reuters
·
Sep 21

Drug Developer ADARx Seeks $1.74 Billion Valuation in US IPO

Reuters
·
Sep 21

Fund Manager Cites AI Drug Development Momentum and Export Growth as Key Drivers for Pharmaceutical Sector Opportunities

Deep News
·
Sep 21

ETF Market Wrap for September 21: Policy Tailwinds and Clearer Outbound Channels Lift Innovative Drug Funds, While Crypto ETFs Surge Throughout the Day

Stock News
·
Sep 21

Hong Kong Equities Close Higher | Hang Seng Index Regains 25,000 Mark, Innovative Drug Shares Rally Broadly, SBP Group Tops Blue-Chip Gainers

Stock News
·
Sep 21

China-Singapore Suzhou Industrial Park Invests Up to RMB 20 Million in Medical Device and Biotech Fund

Stock News
·
Sep 21

Market Shock: A-Share Leader and "Meme Stock" Both Plunge Dramatically

Deep News
·
Sep 21

Anke Biotechnology Advances Novel Drug Candidate as Clinical Trial Application Gains Regulatory Acceptance

Stock News
·
Sep 21

Citi Highlights Policy Boost for Innovative Drugs and Medical Devices, Names Key Sector Picks

Stock News
·
Sep 21

Innovative Drug Sector Heats Up: Spotlight on Pure-Play R&D Developers

Deep News
·
Sep 21

Innovative Drug Stocks Surge Across the Board in Morning Session, with Keymed Bio-B and Akeso Both Climbing Over 9%

Deep News
·
Sep 21

Hong Kong Stock Movers | SBP Group Surges Over 6% as Management Reaffirms Annual Revenue Target, with Newly Approved Innovative Drugs Set to Drive Sustained Sales Growth

Stock News
·
Sep 21

Full-Cycle Management Upgrade: Bringing City-Level Healthcare Straight to the Yao Township Doorstep

Deep News
·
Sep 21

Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports

TIPRANKS
·
Sep 20

Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint

TIPRANKS
·
Sep 20

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

GlobeNewswire
·
Sep 20

From Cash Burn to Cash Flow: Is This Innovative Drug Rally Genuinely Different This Time?

Deep News
·
Sep 20